The researchers found that people homozygous for the risk alleles at both the GLP1R and GIPR sites have a "14.8-fold increased odds" of experiencing moderate to severe vomiting on tirzepatide
Metabolic Research Laboratories support was provided by the following core facilities: Disease Model Core, Histology Core, Imaging Core and Core Biochemical Assay Laboratory (supported by the MRC, grant no
The researchers say dysregulation in brain regions that modulate sleep and pain perception could be the culprit
Treatment might include temporary medication pause, medication to dissolve stones, or in severe cases, gallbladder removal surgery
Fourth, the duration of the trial, 32 weeks, was insufficiently long to demonstrate the durability of glycemic and weight effects of CagriSema [10]